79 results
SC TO-T/A
PNT
POINT Biopharma Global Inc.
8 Nov 23
Third party tender offer statement (amended)
5:06pm
the subheading “Certain Litigation” in Section 16 — “Certain Legal Matters; Regulatory Approvals” of the Offer to Purchase and replacing
SC TO-T/A
PNT
POINT Biopharma Global Inc.
27 Oct 23
Third party tender offer statement (amended)
4:15pm
” of the Offer to Purchase:
“Certain Litigation
In connection with the Offer and Merger Agreement, three complaints have been filed as individual
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
, as well as its ability to attract and retain key personnel while the transaction is pending.
Litigation Risk. The execution of the Merger Agreement … , the completion of the Offer and the consummation of the Merger increases the risk of litigation against POINT.
Interim Operating Covenants. The Merger
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
include giving it to the Department of Justice for civil and criminal litigation and to cities, states, the District of Columbia, and U.S
SC TO-T
EX-99
qa29blnjx7zp8
13 Oct 23
Third party tender offer statement
6:52am
SC14D9C
EX-99.1
391lbul xh6
3 Oct 23
Written communication relating to third party tender offer
7:37am
SC14D9C
EX-99.2
p61wt8mpub 6al3
3 Oct 23
Written communication relating to third party tender offer
7:37am
SC14D9C
EX-2.1
4lozf6mz5b3 1nv
3 Oct 23
Written communication relating to third party tender offer
7:37am
SC14D9C
EX-99.3
z3k und80y5e37lki4r0
3 Oct 23
Written communication relating to third party tender offer
7:37am
8-K
EX-99.2
q3w37bec2t6x8qffvqr
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-99.3
6za ovir36ewobbr
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-2.1
334v4hwjuw64v ju4
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-99.1
ogsy80y
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-99.1
vrm73g7rk 6ueyeo0
14 Aug 23
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
7:21am
ARS
5lid0i52kb1
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-99.1
590rhvdrr4z
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm